On August 13, 2024, SciSparc Ltd., a clinical-stage pharmaceutical company specializing in central nervous system disorders and rare diseases, entered into an exclusive patent license agreement with Polyrizon Ltd. for the out-licensing of its SCI-160 pain therapy program. The agreement grants Polyrizon an exclusive, royalty-bearing license to develop and sublicense the SCI-160 assets. In return, SciSparc will receive shares in Polyrizon valued at $3 million and may also receive additional milestone fees and royalties if certain development targets are met. Concurrently, SciSparc terminated a previous co-development agreement with Polyrizon, dated May 30, 2022. The company publicly announced the licensing agreement on August 16, 2024, through a press release. The SCI-160 program is a proprietary synthetic combination of cannabinoids and N-acylethanolamines, which has shown promise in pre-clinical studies for treating pain without causing significant side effects. The company's CEO, Oz Adler, who also serves on Polyrizon's board of directors, expressed optimism about the potential for royalties and milestone payments from the program without further investment from SciSparc.

On August 13, 2024, SciSparc Ltd., a clinical-stage pharmaceutical company specializing in central nervous system disorders and rare diseases, entered into an exclusive patent license agreement with Polyrizon Ltd. for the out-licensing of its SCI-160 pain therapy program. The agreement grants Polyrizon an exclusive, royalty-bearing license to develop and sublicense the SCI-160 assets. In return, SciSparc will receive shares in Polyrizon valued at $3 million and may also receive additional milestone fees and royalties if certain development targets are met. Concurrently, SciSparc terminated a previous co-development agreement with Polyrizon, dated May 30, 2022. The company publicly announced the licensing agreement on August 16, 2024, through a press release. The SCI-160 program is a proprietary synthetic combination of cannabinoids and N-acylethanolamines, which has shown promise in pre-clinical studies for treating pain without causing significant side effects. The company's CEO, Oz Adler, who also serves on Polyrizon's board of directors, expressed optimism about the potential for royalties and milestone payments from the program without further investment from SciSparc.